Table 3 Cohort characteristics stratified by mortality outcomes
|  | Survived (n = 180, %) | Died (n = 244, %) | p-value |
|---|---|---|---|
Age (years)* | 28.7 ± 15.3 | 31.8 ± 20.8 | 0.080 |
Sex | |||
 Female | 108 (60.0) | 145 (59.4) | 0.921 |
 Male | 72 (40.0) | 99 (40.6) | |
Length of Stay (days)†| 13, (10, 17) | 4, (3, 6) | 0.000 |
Country of Treatment | |||
 Sierra Leone | 119 (66.1) | 171 (70.1) | 0.399 |
 Liberia | 61 (33.9) | 73 (29.9) | |
Rapid diagnostic test for malaria results | |||
 Positive | 17 (9.4) | 31 (12.7) | 0.082 |
 Negative | 94 (52.2) | 101 (41.4) | |
 Not Tested | 69 (38.3) | 112 (45.9) | |
Cycle Threshold Value /Viral Load | |||
 ≥22 (Low Viral Load) | 81 (45.0) | 41 (16.8) | 0.000 |
  < 22 (High Viral Load) | 50 (27.8) | 109 (44.7) | |
 Missing | 49 (27.2) | 94 (38.5) | |
Treatments received first 48 hours of care | |||
 Artemether-lumefantrine | 169 (93.9) | 207 (84.8) | 0.005 |
 ORS | 166 (92.2) | 207 (84.8) | 0.023 |
 Cefixime | 163 (90.6) | 197 (80.7) | 0.006 |
 Multivitamins | 121 (67.2) | 140 (57.4) | 0.044 |
 Ondansetron | 48 (26.7) | 63 (25.8) | 0.911 |
 Vitamin C | 164 (92.8) | 219 (89.8) | 0.740 |
 Zinc Sulphate | 7 (3.9) | 15 (6.1) | 0.378 |
 Vitamin A | 152 (84.4) | 178 (73.0) | 0.006 |
Signs & symptoms first 48 hours of care | |||
 Abnormal Bleeding | 42 (23.3) | 80 (32.8) | 0.039 |
 Coma | 0 (0.0) | 6 (2.5) | 0.041 |
 Diarrhea | 111 (61.7) | 187 (76.6) | 0.001 |
 Dysphagia | 60 (33.3) | 111 (45.5) | 0.012 |
 Dyspnea | 41 (22.8) | 94 (38.5) | 0.001 |
 Jaundice | 2 (1.1) | 23 (9.4) | 0.000 |
 Anorexia | 116 (64.4) | 167 (68.4) | 0.405 |
 Abdominal Pain | 108 (60.0) | 157 (64.3) | 0.363 |
 Vomiting | 104 (57.8) | 150 (61.5) | 0.483 |